Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (04) : 359-363     DOI: 10.3971/j.issn.1000-8578.2022.21.0828
|
Research Progress of Early Recurrence and Cut-off Time of Hepatocellular Carcinoma after Radical Hepatectomy
TAO Changcheng1, ZHANG Kai2, RONG Weiqi1, WU Jianxiong1
1. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 2. Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Download: PDF(2837 KB)   ( 126 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Surgery is the most important way to treat HCC currently. The high recurrence rate after hepatectomy is the most important reason to affect its prognosis, and it is also the key clinical problem to be solved. According to the recurrence time, the recurrence can be divided into early recurrence and late recurrence. The prognosis of patients with early recurrence is worse than that of patients with late recurrence. Therefore, it is very important for surgical decision-making to identify the two kinds of recurrence. This article reviews the research progress of early recurrence cut-off time of hepatocellular carcinoma after radical hepatectomy.
Keywords Hepatocellular carcinoma      Early recurrence      Late recurrence      Recurrence cut-off time     
ZTFLH:  R735.7  
Fund:Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2020L05)
Issue Date: 15 April 2022
 Cite this article:   
TAO Changcheng,ZHANG Kai,RONG Weiqi, et al. Research Progress of Early Recurrence and Cut-off Time of Hepatocellular Carcinoma after Radical Hepatectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 359-363.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0828
http://www.zlfzyj.com/EN/Y2022/V49/I04/359
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
TAO Changcheng
ZHANG Kai
RONG Weiqi
WU Jianxiong
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):
209-249.
[2] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝
癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020, 40(2):
121-138. [Bureau of Medical Administration, National Health
Commission of the People`s Republic of China. Guidelines for
diagnosis and treatment of primary liver cancer in China (2019
edition)[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2020, 40(2):
121-138.]
[3] Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO
classification of tumours of the digestive system[J].
Histopathology, 2020,76(2):182-188.
[4] Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular
Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer
Control, 2017, 24(3): 1073274817729245.
[5] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase Ⅲ randomised, double-blind,
placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[6] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients
with advanced hepatocellular carcinoma previously treated with
sorafenib (KEYNOTE-224): a non-randomised, open-label phase
2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[7] Yang SL, Luo YY, Chen M, et al. A systematic review and metaanalysis
comparing the prognosis of multicentric occurrence and
vs. intrahepatic metastasis in patients with recurrent hepatocellular
carcinoma after hepatectomy[J]. HPB (Oxford), 2017, 19(10):
835-842.
[8] Li XL, Zhu XD, Cai H, et al. Postoperative α-fetoprotein response
predicts tumor recurrence and survival after hepatectomy
for hepatocellular carcinoma: A propensity score matching analysis[J]. Surgery, 2019, 165(6): 1161-1167.
[9] Xu XF, Xing H, Han J, et al. Risk Factors, Patterns, and Outcomes
of Late Recurrence After Liver Resection for Hepatocellular
Carcinoma: A Multicenter Study From China[J]. JAMA Surg,
2019, 154(3): 209-217.
[10] Byeon J, Cho EH, Kim SB, et al. Extrahepatic recurrence of
hepatocellular carcinoma after curative hepatic resection[J].
Korean J Hepatobiliary Pancreat Surg, 2012,16(3):93-97.
[11] Yoh T, Seo S, Taura K, et al. Surgery for Recurrent Hepatocellular
Carcinoma: Achieving Long-term Survival[J]. Ann Surg, 2021,
273(4): 792-799.
[12] 国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌
外科综合治疗的个体化和新策略研究》专家组.肝细胞癌肝切
除术后复发预防和治疗中国专家共识(2020版)[J]. 中国实用外
科杂志, 2021, 41(1): 20-30. [Expert Group of the State Key Project
on Infectious Diseases on "Novel Strategies of Comprehensive
and Individualizd Surgical Treatment of Viral Hepatitis-related
Liver Cancer" from the Ministry of Science and Technology
of China. Chinese expert consensus on the preventation and
management of recurrent hepatocellular carcinoma after hepatic
resection (2020 edition)[J]. Zhongguo Shi Yong Wai Ke Za Zhi,
2021, 41(1): 20-30. ]
[13] Yamamoto Y, Ikoma H, Morimura R, et al. Optimal duration of
the early and late recurrence of hepatocellular carcinoma after
hepatectomy[J]. World J Gastroenterol, 2015, 21(4): 1207-1215.
[14] Chan AWH, Zhong J, Berhane S, et al. Development of pre and
post-operative models to predict early recurrence of hepatocellular
carcinoma after surgical resection[J]. J Hepatol, 2018, 69(6):
1284-1293.
[15] Xing H, Zhang WG, Cescon M, et al. Defining and predicting early
recurrence after liver resection of hepatocellular carcinoma: a
multi-institutional study[J]. HPB (Oxford), 2020, 22(5): 677-689.
[16] Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence
after liver resection for hepatocellular carcinoma: prognostic and
therapeutic implications[J]. Ann Surg, 2006, 243(2): 229-235.
[17] Huang ZY, Liang BY, Xiong M, et al. Long-term outcomes of
repeat hepatic resection in patients with recurrent hepatocellular
carcinoma and analysis of recurrent types and their prognosis:
a single-center experience in China[J]. Ann Surg Oncol, 2012,
19(8): 2515-2525.
[18] Xie DY, Fan HK, Ren ZG, et al. Identifying Clonal Origin
of Multifocal Hepatocellular Carcinoma and Its Clinical
Implications[J]. Clin Transl Gastroenterol, 2019, 10(2): e00006.
[19] Nomoto S, Hishida M, Inokawa Y, et al. Management of
hepatocellular carcinoma should consider both tumor factors and
background liver factors[J]. Hepatobiliary Surg Nutr, 2014, 3(2):
82-85.
[20] Wang B, Xia CY, Lau WY, et al. Determination of clonal origin of
recurrent hepatocellular carcinoma for personalized therapy and
outcomes evaluation: a new strategy for hepatic surgery[J]. J Am
Coll Surg, 2013, 217(6): 1054-1062.
[21] Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and
clonality relationship between primary and recurrent hepatocellular
carcinoma[J]. Gastroenterology, 2000, 119(2): 431-440.
[22] Miao R, Luo H, Zhou H, et al. Identification of prognostic
biomarkers in hepatitis B virus-related hepatocellular carcinoma
and stratification by integrative multi-omics analysis[J]. J Hepatol,
2014, 61(4): 840-849.
[23] Ueno S, Aoki D, Maeda T, et al. Preoperative assessment of
multicentric occurrence in synchronous small and multiple
hepatocellular carcinoma based on image-patterns and histological
grading of non-cancerous region[J]. Hepatol Res, 2004, 29(1):
24-30.
[24] Matsuda M, Fujii H, Kono H, et al. Surgical treatment of recurrent
hepatocellular carcinoma based on the mode of recurrence: repeat
hepatic resection or ablation are good choices for patients with
recurrent multicentric cancer[J]. J Hepatobiliary Pancreat Surg,
2001, 8(4): 353-359.
[25] Li Q, Wang J, Juzi JT, et al. Clonality analysis for multicentric
origin and intrahepatic metastasis in recurrent and primary
hepatocellular carcinoma[J]. J Gastrointest Surg, 2008, 12(9):
1540-1547.
[26] Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e
antigen is associated with higher risk of early recurrence and
poorer survival in patients after curative resection of hepatitis
B-related hepatocellular carcinoma[J]. J Hepatol, 2007, 47(5):
684-690.
[27] Zhang H, Han J, Xing H, et al. Sex difference in recurrence and
survival after liver resection for hepatocellular carcinoma: A
multicenter study[J]. Surgery, 2019, 165(3): 516-524.
[28] Kim WJ, Lim TW, Park PJ, et al. Prognostic markers affecting the
early recurrence of hepatocellular carcinoma with liver cirrhosis
after curative resection[J]. Int J Biol Markers, 2019, 34(2): 123-131.
[29] Guo Y, Chua DW, Koh YX, et al. Preoperative Predictors
Including the Role of Inflammatory Indices in Predicting Early
Recurrence After Re-resection for Recurrent Hepatocellular
Carcinoma[J]. World J Surg, 2019, 43(10): 2587-2594.
[30] Jung SM, Kim JM, Choi GS, et al. Characteristics of Early
Recurrence After Curative Liver Resection for Solitary
Hepatocellular Carcinoma[J]. J Gastrointest Surg, 2019, 23(2):
304-311.
[32] Sohn W, Paik YH, Kim JM, et al. HBV DNA and HBsAg levels as
risk predictors of early and late recurrence after curative resection
of HBV-related hepatocellular carcinoma[J]. Ann Surg Oncol,
2014, 21(7): 2429-2435.
[33] Wang MD, Li C, Liang L, et al. Early and Late Recurrence of
Hepatitis B Virus-Associated Hepatocellular Carcinoma[J].
Oncologist, 2020, 25(10): e1541-1551.
[34] Imai K, Allard MA, Benitez CC, et al. Early Recurrence After
Hepatectomy for Colorectal Liver Metastases: What Optimal
Definition and What Predictive Factors?[J]. Oncologist, 2016,
21(7): 887-894.
[35] Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis
for early and late intrahepatic recurrence after resection of
hepatocellular carcinoma[J]. Cancer, 2000, 89(3): 500-507.
[36] Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral
Therapy Not Associated With Recurrence of Hepatocellular
Carcinoma in a Multicenter North American Cohort Study[J].
Gastroenterology, 2019, 156(6): 1683-1692.e1.
[37] Xing H, Sun LY, Yan WT, et al. Repeat hepatectomy for patients
with early and late recurrence of hepatocellular carcinoma: A
multicenter propensity score matching analysis[J]. Surgery, 2021,
169(4): 911-920.
Related articles from Frontiers Journals
[1] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[2] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[3] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[4] ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
[5] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[6] XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
[7] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[8] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[9] CUI Honglei, ZHANG Xiaodan, GUO Danfeng, YAN Zhiping, GUO Wenzhi, ZHANG Shuijun. Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 438-443.
[10] ZHOU Yongjie, WANG Zhengfeng, YAN Jun, WANG Haiping, XU Wen, ZHOU Wence. Value of Preoperative Lactate Dehydrogenase-to-Albumin Ratio Combined with AFP in Evaluating Prognosis of Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 347-351.
[11] ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong. Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 213-218.
[12] CHEN Long, LIU Yujie, TIAN Suqing, WANG Cuiying, HE Donglei. Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 53-57.
[13] PANG Kangqing, MA Hongde, YANG Rulei, PANG Guohong. Expression and Clinical Significance of Serum PTX3 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1078-1081.
[14] SONG Yanzhou, ZHANG Kun, CHEN Qijun, WEI Wenping, ZHAO Xin, LI Zhiwei, LI Wei. Experiment on Inhibiting NEK7 to Promote Apoptosis of Hepatocellular Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 929-933.
[15] XU Gang, BU Shanshan, WANG Xiushen, GE Hong. Correlation Between cyclin G1 Expression and Efficacy of Radiotherapy on Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 958-962.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed